Abstract
For anesthetic drugs undergoing nonorgan-based elimination, there is a definite trend towards using pharmacokinetic (PK) models in which elimination can occur from both central (k10 ) and peripheral compartments(k20 ). As the latter cannot be assessed directly, assumptions have to be made regarding its value. The primary purpose of this paper is to evaluate the impact of assuming various degrees of peripheral elimination on the estimation of PK parameters. For doing so, an explanatory model is presented where previously published data from our laboratory on three muscle relaxants, i.e., atracurium, doxacurium, and mivacurium, are used for simulations. The mathematical aspects for this explanatory model as well as for two specific applications are detailed. Our simulations show that muscle relaxants having a short elimination half-life are more affected by the presence of peripheral elimination as their distribution phase occupies the major proportion of their total area under the curve. Changes in the exit site dependent PK parameters (Vdss ) are also mostly significant when k20 is smaller than k10 . Although the physiological processes that determine drug distribution and those affecting peripheral elimination are independent, the two are mathematically tied together in the two-compartment model with both central and peripheral elimination. It follows that, as greater importance is given to k20 , the rate of transfer from the central compartment (k12 ) increases. However, as a result of a proportional increase in the volume of the peripheral compartment, peripheral concentrations remain unchanged whether or not peripheral elimination is assumed. These findings point out the limitations of compartmental analysis when peripheral elimination cannot be measured directly.
Similar content being viewed by others
REFERENCES
E. Nakashima and L. Benet. General treatment of mean residence time, clearance, and volume parameters in linear mamillary models with elimination from any compartment. J. Pharmacokin. Biopharm. 16:475-492 (1988).
L. Z. Benet. General treatment of linear mamillary models with elimination from any compartment as used in pharmacokinetics. J. Pharm. Sci. 61:536-541 (1972).
D. M. Fisher, P. C. Canfell, M. R. Fahey, J. I. Rosen, S. M. Rupp, L. B. Sheiner, and R. D. Miller. Elimination of atracurium in humans: Contribution of Hofmann elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 65:6-12 (1986).
C. A. Lien, V. D. Schmith, M. R. Belmont, A. Abalos, D. F. Kisor, and J. J. Savarese. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/ opioid/ barbiturate anesthesia. Anesthesiology 84:300-308 (1996).
S. S. Sorooshian, M. A. Stafford, N. B. Eastwood, A. H. Boyd, C. J. Hull, and P. M. Wright. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology 84:1083-1091 (1996).
V. D. Schmith, J. Fielder-Kelly, L. Phillips, and T. H. Grasela. Dose proportionality of cisatracurium. J. Clin. Pharmacol. 37:625-629 (1997).
V. D. Schmith, J. Fielder-Kelly, L. Phillips, and T. H. Grasela. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium. Pharm Research 14:91-97 (1997).
T.-V. Tran, P. Fiset, and F. Varin. Pharmacokionetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth. Analg. 87:1158-1163 (1998).
D. M. Fisher. (Almost) Everything you learned about pharmacokinetics was (somewhat) wrong! Anesth. Analg. 83:901-903 (1996).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
J. Ducharme, F. Varin, and F. Donati. Pharmacokinetics and pharmacodynamics of a second dose of atracurium in anaesthetised patients. Clin. Drug Invest. 9(2):98-110 (1995).
Y. Zhu, G. Audibert, F. Donati, and F. Varin. Pharmacokinetic-pharmacodynamic modeling of doxacurium: Effect of input rate. J. Pharmacokin. Biopharm. 25:23-37 (1997).
M. Lacroix, F. Donati, and F. Varin. Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. Anesthesiology 86:322-330 (1997).
S. Ward and A. M. Neill. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br. J. Anaesth. 55:1169-1172 (1983).
D. L. Dresner, S. J. Basta, H. H. Ali, A. F. Schwartz, P. B. Embree, W. A. Wargin, A. A. Lai, K. A. Brady, and J. J. Savarese. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth. Analg. 71:498-502 (1990).
W. C. Ummenhofer, S. M. Brown, and C. M. Bernards. Acethylcholinesterase and butyrylcholinesterase are expressed in the spinal meninges of monkeys and pigs. Anesthesiology 88:1259-1265 (1998).
F. Varin, J. Ducharme, J. G. Besner, and Y. Theoret. Determination of atracurium and laudanosine in human plasma by high-peformance liquid chromatography. J. Chromatogr. 435:319-327 (1990).
L. P. Gariepy, F. Varin, F. Donati, Y. Salib, and D. R. Bevan. Influence of aging on the pharmacokinetics and pharmacodynamics of doxacurium. Clin. Pharmacol. Ther. 53:340-347 (1993).
M. Lacroix, T. M. Tu, F. Donati, and F. Varin. High-performance liquid chromatographic assays with fluorometric detection for mivacurium isomers and their metabolites in human plasma. J. Chromatog B. 663:297-307 (1995).
S. Niazi. Volume of distribution as a function of time. J. Pharm. Sci. 65:452-454 (1976).
S. Riegelman, J. Loo, and M. Rowland. Concept of a volume of distribution and possible errors in evaluation of this parameter. J. Pharm. Sci. 57:128-133 (1968).
M. Gibaldi, R. Nagashima, and G. Levy. Relationship between drug concentration in plasma or serum and amount of drug in the body. J. Pharm. Sci. 58:193-197 (1968).
J. G. Wagner and J. I. Northam. Estimation of volume of distribution and half-life of a compound after rapid intravenous injection. J. Pharm. Sci. 54:529-531 (1967).
M. Gibaldi and S. Feldman. Route of administration and drug metabolism. European J. Pharmacol. 19:323-329 (1972).
W. J. Jusko and M. Gibaldi. Effects of change in elimination on various parameters of the two-compartment open model. J. Pharm. Sci. 61:1270-1273 (1972).
Scientific Consulting Inc. WinNonlin, Cary, NC, 1995.
R. L. Stiller, D. Ryan Cook, and S. Chakravorti. In vitro degradation of atracurium in human plasma. Br. J. Anaesth. 57:1085-1088 (1985).
S. Ward, A. M. Neill, B. C. Weatherley, and I. M. Corall. Pharmacokinetics of atracurium bezylate in healthy patients (after a single I.V. bolus dose) Br. J. Anaesth. 55:113-117 (1983).
C. J. Hull. A model for atracurium? [Editorial]. Br. J. Anaesth. 55:95-96 (1983).
R. M. Welch, A. Brown, J. Ravitch, and R. Dahl. The in vitro degradation of cisatracurium, the R, cis-R-isomer of atracurium, in human and rat plasma. Clin. Pharmacol. Ther. 58:132-142 (1995).
D. F. Kisor, V. D. Schmith, W. A. Wargin, C. A. Lien, E. Ornstein, and R. Cook. Importance of the organ-independent elimination of cisatracurium Anesth. Analg. 83:1065-1071 (1996).
M. Gibaldi and D. Perrier. Pharmacokinetics (Drugs and pharmaceutical sciences) Vol. 15, 2nd ed., Marcel Dekker, NY, 1982.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laurin, J., Nekka, F., Donati, F. et al. Assuming Peripheral Elimination: Its Impact on the Estimation of Pharmacokinetic Parameters of Muscle Relaxants. J Pharmacokinet Pharmacodyn 27, 491–512 (1999). https://doi.org/10.1023/A:1023286329945
Published:
Issue Date:
DOI: https://doi.org/10.1023/A:1023286329945